Oncology Institute Inc
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as education… Read more
Oncology Institute Inc (TOI) - Total Liabilities
Latest total liabilities as of September 2025: $175.89 Million USD
Based on the latest financial reports, Oncology Institute Inc (TOI) has total liabilities worth $175.89 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oncology Institute Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Oncology Institute Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oncology Institute Inc Competitors by Total Liabilities
The table below lists competitors of Oncology Institute Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Holly Corp
SHG:600128
|
China | CN¥3.66 Billion |
|
Tanla Platforms Limited
NSE:TANLA
|
India | ₹10.94 Billion |
|
Hangzhou Weiguang Electronic Co Ltd
SHE:002801
|
China | CN¥342.62 Million |
|
Liaoning Fu-An
SHG:603315
|
China | CN¥1.49 Billion |
|
Village Farms International Inc
NASDAQ:VFF
|
USA | $113.02 Million |
|
Matrix Service Co
NASDAQ:MTRX
|
USA | $512.64 Million |
|
Sichuan Goldstone Orient New Material Equipment Co Ltd
SHE:300434
|
China | CN¥484.37 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩257.46 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Oncology Institute Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -14.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncology Institute Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncology Institute Inc (2019–2024)
The table below shows the annual total liabilities of Oncology Institute Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $169.13 Million | +11.11% |
| 2023-12-31 | $152.22 Million | +9.91% |
| 2022-12-31 | $138.49 Million | +39.49% |
| 2021-12-31 | $99.28 Million | +164.13% |
| 2020-12-31 | $37.59 Million | +117.29% |
| 2019-12-31 | $17.30 Million | -- |